
|Articles|January 5, 2022
Tools4Patient Announces Name Change to Cognivia
Advertisement
Cognivia announced a new name for the company formerly known as Tools4Patient. The transition to Cognivia more closely reflects the company's mission to “quantify the power of the mind” and integrate this information into data analyses to optimize and accelerate drug development.
This name change expresses the evolution of the company since it was founded eight years ago. As part of this maturation, Cognivia has built the evidence basis for its technologies through multiple clinical trials and has become a partner of pharma companies, biotechs, and CROs. Cognivia’s solutions are focused in areas that have posed significant challenges to drug development, including the placebo response and medication adherence in clinical trials.
Advertisement
Related to this article

In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.

In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.

RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.

In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.

In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.

In this Q&A, Sylviane de Viron of CluePoints and Abigail Dirks, MS, of Tufts CSDD discuss the findings of a collaborative study quantifying the financial value of RBQM, why time savings emerged as the largest driver, and what sponsors struggling to justify adoption now have that they didn't before.

In this video interview, Claire Riches, VP of clinical solutions at Citeline, walks through the categories of hidden protocol risk that AI-driven simulations can identify—from overly restrictive eligibility criteria to patient dropout patterns and structural trial assumptions.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-World Evidence Is Moving Upstream: Is the Data Infrastructure Ready?
2
Sponsor Oversight in an Outsourced Trial: What Good Looks Like and How to Evidence It
3
The Data Inputs That Matter Most When Pressure-Testing a Protocol's Feasibility
4
ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney Cancer Approval
5

